PDF(Pubmed)
Abstract：
BACKGROUND: Bevacizumab (Bev) is a humanized monoclonal antibody that targets vascular endothelial growth factor A and is primarily used for the treatment of various solid tumors. Aortic dissection (AD) is a severe vascular disease caused by the tearing of the intimal layer of the aorta or bleeding within the aortic wall, resulting in the separation of different layers of the aortic wall. However, the pathogenesis is not fully understood. Some studies have suggested that Bev treatment is associated with the occurrence of AD.
METHODS: A 67-year-old Chinese male was diagnosed with rectal cancer accompanied by liver and lung metastasis. Three days after starting combined chemotherapy with Bev, the patient developed persistent abdominal pain. Abdominal CT scan revealed celiac trunk AD in the abdominal aorta.
METHODS: The patient was diagnosed with rectal cancer accompanied by liver and lung metastases. Abdominal CT tomography revealed a celiac trunk AD.
METHODS: Somatostatin combined with valsartan was used to control blood pressure. The patient was subsequently referred for vascular surgery and underwent an abdominal aortic angiography. Conservative treatment was continued.
RESULTS: Three months after the initiation of treatment, follow-up abdominal CT scans showed stability in the condition of celiac trunk AD, with no abdominal pain or hypertension. There were no signs of worsening dissection, aneurysm formation, or inadequate perfusion of end organs.
CONCLUSIONS: There may be a connection between Bev and elevated blood pressure as well as celiac trunk AD.
METHODS: A 67-year-old Chinese male was diagnosed with rectal cancer accompanied by liver and lung metastasis. Three days after starting combined chemotherapy with Bev, the patient developed persistent abdominal pain. Abdominal CT scan revealed celiac trunk AD in the abdominal aorta.
METHODS: The patient was diagnosed with rectal cancer accompanied by liver and lung metastases. Abdominal CT tomography revealed a celiac trunk AD.
METHODS: Somatostatin combined with valsartan was used to control blood pressure. The patient was subsequently referred for vascular surgery and underwent an abdominal aortic angiography. Conservative treatment was continued.
RESULTS: Three months after the initiation of treatment, follow-up abdominal CT scans showed stability in the condition of celiac trunk AD, with no abdominal pain or hypertension. There were no signs of worsening dissection, aneurysm formation, or inadequate perfusion of end organs.
CONCLUSIONS: There may be a connection between Bev and elevated blood pressure as well as celiac trunk AD.
摘要：
背景：贝伐单抗（Bev）是一种靶向血管内皮生长因子A的人源化单克隆抗体，主要用于治疗各种实体瘤。主动脉夹层（AD）是由主动脉内膜层撕裂或主动脉壁内出血引起的严重血管疾病，导致主动脉壁不同层的分离。然而,发病机制尚不完全清楚。一些研究表明，Bev治疗与AD的发生有关。
方法：一名67岁的中国男性被诊断为直肠癌并伴有肝和肺转移。开始与Bev联合化疗三天后，患者出现持续性腹痛。腹部CT扫描显示腹主动脉中的腹腔干AD。
方法：患者诊断为直肠癌伴肝、肺转移。腹部CT断层扫描显示腹腔干AD。
方法：用生长抑素联合缬沙坦控制血压。该患者随后被转介接受血管手术，并接受了腹主动脉造影。继续保守治疗。
结果：治疗开始后三个月，随访腹部CT扫描显示腹腔干AD病情稳定，没有腹痛或高血压。没有解剖恶化的迹象,动脉瘤形成,或最终器官灌注不足。
结论：Bev与血压升高以及腹腔干AD之间可能存在联系。
方法：一名67岁的中国男性被诊断为直肠癌并伴有肝和肺转移。开始与Bev联合化疗三天后，患者出现持续性腹痛。腹部CT扫描显示腹主动脉中的腹腔干AD。
方法：患者诊断为直肠癌伴肝、肺转移。腹部CT断层扫描显示腹腔干AD。
方法：用生长抑素联合缬沙坦控制血压。该患者随后被转介接受血管手术，并接受了腹主动脉造影。继续保守治疗。
结果：治疗开始后三个月，随访腹部CT扫描显示腹腔干AD病情稳定，没有腹痛或高血压。没有解剖恶化的迹象,动脉瘤形成,或最终器官灌注不足。
结论：Bev与血压升高以及腹腔干AD之间可能存在联系。
